Document Detail


Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
MedLine Citation:
PMID:  12022239     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Our aim was to determine whether the aldosterone synthase (CYP11B2) -344 C/T polymorphism was associated with the blood pressure (BP)-lowering response to antihypertensive treatment. METHODS: Patients with mild-to-moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind study to receive treatment with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan (n = 43), or the beta1-adrenergic receptor blocker atenolol (n = 43). The aldosterone synthase (CYP11B2) -344 C/T polymorphism was analyzed using solid-phase minisequencing and related to BP reduction after 3 months treatment. Serum aldosterone levels were measured. RESULTS: After 3 months treatment the mean reductions in BP were similar for both treatment groups. When assessing the systolic BP reduction in the irbesartan group, patients with the TT variant had a more pronounced reduction (-21 +/- 19 SD mm Hg, n = 17) than both the TC (-14 +/- 18 mm Hg, n= 18) and CC (0 +/- 17 mm Hg, n = 8) genotypes (P = .04). There was no association between this polymorphism and the diastolic BP response. The -344 C/T polymorphism was not associated with the BP response to atenolol. Nor was it related to the baseline serum aldosterone level. CONCLUSIONS: The aldosterone synthase -344 C/T polymorphism was related to the BP-lowering response in hypertensive patients treated with the AT1-receptor antagonist irbesartan.
Authors:
Lisa Kurland; Håkan Melhus; Julia Karlsson; Thomas Kahan; Karin Malmqvist; Peter Ohman; Fredrik Nyström; Anders Hägg; Lars Lind
Related Documents :
18091749 - Blood pressure variability causes spurious identification of hypertension in clinical s...
7755939 - Effects of intensified blood-pressure reduction on renal function and albumin excretion...
7861449 - Lateral cortical impact injury in rats: cerebrovascular effects of varying depth of cor...
10078889 - Blood pressure behavior in the nursing home: implications for diagnosis and treatment o...
15462109 - Should the preservation of residual renal function cost volume overload and its consequ...
17293739 - Prehypertension as a risk factor for cardiovascular diseases.
17756949 - Antiferromagnetism in pressure-amorphized fe2sio4.
9758269 - Biochemical hemodynamic and hematological changes during transcervical resection of the...
9077619 - The natural history of a positive response to transfundal pressure in women at risk for...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of hypertension     Volume:  15     ISSN:  0895-7061     ISO Abbreviation:  Am. J. Hypertens.     Publication Date:  2002 May 
Date Detail:
Created Date:  2002-05-22     Completed Date:  2002-11-08     Revised Date:  2009-02-24    
Medline Journal Info:
Nlm Unique ID:  8803676     Medline TA:  Am J Hypertens     Country:  United States    
Other Details:
Languages:  eng     Pagination:  389-93     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Uppsala University Hospital, Sweden. lisa.kurland@medsci.uu.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use*
Aldosterone / blood
Aldosterone Synthase / genetics*
Antihypertensive Agents / therapeutic use*
Atenolol / therapeutic use*
Base Sequence / genetics
Biphenyl Compounds / therapeutic use*
Blood Pressure
Cytosine
Double-Blind Method
Female
Humans
Hypertension / blood,  drug therapy*,  genetics*,  physiopathology
Hypertrophy, Left Ventricular / drug therapy
Male
Middle Aged
Polymorphism, Genetic*
Receptor, Angiotensin, Type 1
Receptors, Angiotensin / antagonists & inhibitors
Tetrazoles / therapeutic use*
Thymine
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Antihypertensive Agents; 0/Biphenyl Compounds; 0/Receptor, Angiotensin, Type 1; 0/Receptors, Angiotensin; 0/Tetrazoles; 138402-11-6/irbesartan; 29122-68-7/Atenolol; 52-39-1/Aldosterone; 65-71-4/Thymine; 71-30-7/Cytosine; EC 1.14.15.4/Aldosterone Synthase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overwe...
Next Document:  Prevalence of hyperhomocysteinemia in an elderly population.